JOINT FILING AGREEMENTJoint Filing Agreement • November 9th, 2020 • Thomvest Asset Management Ltd. • Pharmaceutical preparations
This will confirm the agreement among the undersigned that the Schedule 13D filed on or about this date and any amendments thereto with respect to beneficial ownership by the undersigned of the common shares, no par value, of Liminal Biosciences Inc. is being filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 27th, 2020 • Thomvest Asset Management Ltd. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (“Amendment”) is made as of November 25, 2020, by and among Liminal BioSciences Inc., a Canadian corporation (the “Company”), and the undersigned investors who are party to that certain Securities Purchase Agreement dated as of October 29, 2020 (the “Purchase Agreement”), by and among the Company and the investors party hereto. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement.
